P108
Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung CancerIrinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck CancerErlotinib in Treating Patients With Breast Cancer That Can Be Removed by SurgeryBortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck CancerErlotinib in Treating Patients With Advanced Non-Small Cell Lung CancerRole of Biomarkers in Muscle Pain and Joint Pain in Patients With Solid Tumors Receiving PaclitaxelPotential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor3T MRI Biomarkers of Glioma Treatment ResponseFluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction CancerBortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or MelanomaPemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck CancerChemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & DysphagiaAfatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckAnimal-Assisted Interactions in Children With Life-Threatening Conditions and Their ParentsGefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the BreastGlutamine PET Imaging Colorectal CancerPevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase InhibitorsFulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast CancerInherited CAncer REgistryNashville Early Diagnosis Lung Cancer ProjectLinifanib in Treating Patients With Advanced, Refractory Colorectal CancerAurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV MelanomaTrial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast CancerMK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast CancerOpioid Titration in the Hospice Setting: Barriers Assessment and Modification of the Model Order Sheet and ProtocolAtezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast CancerFinding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell TransplantRituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System LymphomaStudying Health Outcomes After Treatment in Patients With RetinoblastomaIfetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence
P859
Q47005604-2d0b1de9-414b-014f-3f81-22b213e5403dQ56426185-317ea204-41b9-130c-e8bc-5450f819dffdQ82683894-38ff57b2-478a-a779-2b34-d4fdea902b46Q86531385-bfb6ef9d-4627-32c2-0b72-e9db51b60bc2Q87654490-4599e426-4dcd-e012-0415-640cf99a2a7fQ90280624-aceb45e4-4c54-6313-929e-2954015bebbeQ90406471-05dbcc6a-4a62-90dc-ee16-3c60a2b616b5Q91486577-542530b1-43c1-5fe2-a742-79fcb4dae402
P1416
Q61707464-CE632CB8-E26E-4EBE-AAC0-37CE4B3C386BQ61914995-95BCB891-CBDE-4476-8911-052DC0D18CEDQ61915574-79D6BFCA-DA7F-4427-AA0A-79CB9FEA6C2AQ61921488-B9B5BE74-D6DF-4420-B4E1-58A0D8512AD2Q61922374-4469AC54-6670-4182-B956-347DA1D34C73Q61936559-110A8DE9-124F-4DB9-A369-77852CEA4485Q61936562-4D59EAA3-2512-48F4-868A-99095CF2209CQ61969599-D5F5B865-1234-4108-952C-12A1ABDE5D18Q61978917-C954D8A7-E70E-46F4-B3C3-EA0193D298DCQ61979006-966F7646-1FE4-4896-AB58-DAFC93F002D6Q61980113-A9E1558E-20FE-46F8-9A6F-309AD0D14A51Q61980136-8A244D2B-5C15-432D-98B3-BB9746425BF0Q62025275-542D705B-D873-4612-B8A4-3ACF8B79A466Q62031823-DD75B690-3585-4E0B-924E-7E1F7029164EQ62111106-719F80F7-0555-43F9-A00D-AD3900A8000BQ62812498-54F0A68E-0B1B-4A03-9CEE-B17E77F49EAAQ63010790-12E252AB-E30A-4FE9-B780-CCFFED642ED7Q63010802-B2266A32-70E6-429C-802D-0509EF07144BQ63012277-0BFA0198-1796-489C-8FAE-59E6EEAD678CQ63321029-44DA5F2C-B572-430B-8888-9FAF8EF102AEQ63333722-FF4C4DDB-DDDC-4CCC-9EE4-E9C6AF2E9552Q63337983-E34517E3-69F8-4C0A-B80E-F5DE304BCFFFQ63340258-1308A58C-00F3-4828-A1CF-1BB7A0F3CD36Q63340259-1B37FFD9-E749-4B99-A050-2C6B0C40AF52Q63341159-9C263CA2-836D-452E-A2D0-D9FDF6308321Q63398179-F268A6C5-97F4-4E63-8517-7E959A0C82ECQ63405142-0DE82E5B-AC21-4CEE-992C-9E32FD6202EBQ63571756-0001C672-2894-4BEA-AD1B-812AE5637C4CQ63576732-2BB590FF-3462-4878-9D74-145BD3189E04Q63599209-554953BE-08A5-43D3-B239-7F114CFC5740
P859
description
cancer research and treatment institute
@en
name
Vanderbilt-Ingram Cancer Center
@en
type
label
Vanderbilt-Ingram Cancer Center
@en
prefLabel
Vanderbilt-Ingram Cancer Center
@en
P31
P571
1993-01-01T00:00:00Z